242 related articles for article (PubMed ID: 15731267)
1. The global transcriptional effects of the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated by the E6AP ubiquitin ligase.
Kelley ML; Keiger KE; Lee CJ; Huibregtse JM
J Virol; 2005 Mar; 79(6):3737-47. PubMed ID: 15731267
[TBL] [Abstract][Full Text] [Related]
2. The stability of the human papillomavirus E6 oncoprotein is E6AP dependent.
Tomaić V; Pim D; Banks L
Virology; 2009 Oct; 393(1):7-10. PubMed ID: 19700180
[TBL] [Abstract][Full Text] [Related]
3. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background.
Massimi P; Shai A; Lambert P; Banks L
Oncogene; 2008 Mar; 27(12):1800-4. PubMed ID: 17934525
[TBL] [Abstract][Full Text] [Related]
4. The E6AP ubiquitin ligase is required for transactivation of the hTERT promoter by the human papillomavirus E6 oncoprotein.
Liu X; Yuan H; Fu B; Disbrow GL; Apolinario T; Tomaic V; Kelley ML; Baker CC; Huibregtse J; Schlegel R
J Biol Chem; 2005 Mar; 280(11):10807-16. PubMed ID: 15655249
[TBL] [Abstract][Full Text] [Related]
5. The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)-positive and HPV-negative cells.
Talis AL; Huibregtse JM; Howley PM
J Biol Chem; 1998 Mar; 273(11):6439-45. PubMed ID: 9497376
[TBL] [Abstract][Full Text] [Related]
6. Multiple regions of E6AP (UBE3A) contribute to interaction with papillomavirus E6 proteins and the activation of ubiquitin ligase activity.
Drews CM; Brimer N; Vande Pol SB
PLoS Pathog; 2020 Jan; 16(1):e1008295. PubMed ID: 31971989
[TBL] [Abstract][Full Text] [Related]
7. HPV16 E6-induced and E6AP-dependent inhibition of the transcriptional coactivator hADA3 in human cervical carcinoma cells.
Hu Y; Ye F; Lu W; Hong D; Wan X; Xie X
Cancer Invest; 2009 Mar; 27(3):298-306. PubMed ID: 19194825
[TBL] [Abstract][Full Text] [Related]
8. Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6.
Matsumoto Y; Nakagawa S; Yano T; Takizawa S; Nagasaka K; Nakagawa K; Minaguchi T; Wada O; Ooishi H; Matsumoto K; Yasugi T; Kanda T; Huibregtse JM; Taketani Y
J Med Virol; 2006 Apr; 78(4):501-7. PubMed ID: 16482544
[TBL] [Abstract][Full Text] [Related]
9. Identification of E6AP-independent degradation targets of HPV E6.
Vats A; Thatte J; Banks L
J Gen Virol; 2019 Dec; 100(12):1674-1679. PubMed ID: 31609195
[TBL] [Abstract][Full Text] [Related]
10. Binding of human papillomavirus type 16 E6 to E6AP is not required for activation of hTERT.
Sekaric P; Cherry JJ; Androphy EJ
J Virol; 2008 Jan; 82(1):71-6. PubMed ID: 17942561
[TBL] [Abstract][Full Text] [Related]
11. The human papillomavirus E6 oncogene represses a cell adhesion pathway and disrupts focal adhesion through degradation of TAp63β upon transformation.
Ben Khalifa Y; Teissier S; Tan MK; Phan QT; Daynac M; Wong WQ; Thierry F
PLoS Pathog; 2011 Sep; 7(9):e1002256. PubMed ID: 21980285
[TBL] [Abstract][Full Text] [Related]
12. E6 proteins from high-risk HPV, low-risk HPV, and animal papillomaviruses activate the Wnt/β-catenin pathway through E6AP-dependent degradation of NHERF1.
Drews CM; Case S; Vande Pol SB
PLoS Pathog; 2019 Apr; 15(4):e1007575. PubMed ID: 31002735
[TBL] [Abstract][Full Text] [Related]
13. A ubiquitin variant-based affinity approach selectively identifies substrates of the ubiquitin ligase E6AP in complex with HPV-11 E6 or HPV-16 E6.
Ebner FA; Sailer C; Eichbichler D; Jansen J; Sladewska-Marquardt A; Stengel F; Scheffner M
J Biol Chem; 2020 Oct; 295(44):15070-15082. PubMed ID: 32855237
[TBL] [Abstract][Full Text] [Related]
14. Cellular steady-state levels of "high risk" but not "low risk" human papillomavirus (HPV) E6 proteins are increased by inhibition of proteasome-dependent degradation independent of their p53- and E6AP-binding capabilities.
Kehmeier E; Rühl H; Voland B; Stöppler MC; Androphy E; Stöppler H
Virology; 2002 Jul; 299(1):72-87. PubMed ID: 12167343
[TBL] [Abstract][Full Text] [Related]
15. Association of papillomavirus E6 proteins with either MAML1 or E6AP clusters E6 proteins by structure, function, and evolutionary relatedness.
Brimer N; Drews CM; Vande Pol SB
PLoS Pathog; 2017 Dec; 13(12):e1006781. PubMed ID: 29281732
[TBL] [Abstract][Full Text] [Related]
16. Human Papillomavirus 16 (HPV-16), HPV-18, and HPV-31 E6 Override the Normal Phosphoregulation of E6AP Enzymatic Activity.
Thatte J; Banks L
J Virol; 2017 Nov; 91(22):. PubMed ID: 28835500
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus type 16 E6 induces self-ubiquitination of the E6AP ubiquitin-protein ligase.
Kao WH; Beaudenon SL; Talis AL; Huibregtse JM; Howley PM
J Virol; 2000 Jul; 74(14):6408-17. PubMed ID: 10864652
[TBL] [Abstract][Full Text] [Related]
18. Structure based identification and characterization of flavonoids that disrupt human papillomavirus-16 E6 function.
Cherry JJ; Rietz A; Malinkevich A; Liu Y; Xie M; Bartolowits M; Davisson VJ; Baleja JD; Androphy EJ
PLoS One; 2013; 8(12):e84506. PubMed ID: 24376816
[TBL] [Abstract][Full Text] [Related]
19. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter.
Veldman T; Liu X; Yuan H; Schlegel R
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8211-6. PubMed ID: 12821782
[TBL] [Abstract][Full Text] [Related]
20. Structure of the E6/E6AP/p53 complex required for HPV-mediated degradation of p53.
Martinez-Zapien D; Ruiz FX; Poirson J; Mitschler A; Ramirez J; Forster A; Cousido-Siah A; Masson M; Vande Pol S; Podjarny A; Travé G; Zanier K
Nature; 2016 Jan; 529(7587):541-5. PubMed ID: 26789255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]